Gilead and Agenus sign cancer drug development deal
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of...
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of...
Healthtech will rise to prominence in 2019 as Big Data and Artificial Intelligence (AI) become...
AstraZeneca and its partner Merck have published positive results from SOLO-3 phase III trial of...
Recently, the National Health Service (NHS) in the UK announced they have completed negotiations over...
In this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based...
The UK’s pricing regulator the National Institutes of Health and Care Excellence (NICE) has expanded...
Clinical trial enrolment is a long-standing problem for drug developers, so it is hoped that...
GlaxoSmithKline (GSK) and Pfizer have agreed to merge their consumer health businesses to create a...
China is not only potentially the largest healthcare market in the world, but it is...
Verzenio's Phase II trial should start in early 2019 after funding was approved by sponsor...